Statins and venous thromboembolism: A novel effect of statins?

Current Medical Research and Opinion

Volumn 25, Issue 7, 2009, Pages 1807-1809

  Paraskevas, Kosmas I ^a   Bessias, Nikolaos ^a   Perdikides, Theodossios P ^b   Mikhailidis, Dimitri P ^c  

^a RED CROSS HOSPITAL   (Greece)

^b Hellenic Air Force Hospital   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Rosuvastatin; Statin; Venous thromboembolism

Indexed keywords

C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN;

ADULT; AGED; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LUNG EMBOLISM; MALE; MORTALITY; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; REVIEW; RISK REDUCTION; STROKE; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PLACEBOS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SULFONAMIDES; VENOUS THROMBOEMBOLISM;

EID: 67650457574     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903052591     Document Type: Review

References (27)

1. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207
2. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009;360:1851-61
3. Chan DC, Watts GF. Pharmacological regulation of dyslipoproteinaemia in insulin resistant states. Curr Vasc Pharmacol 2008; 6:67-77
4. Harley CR, Gandhi SK, Heien H, et al. Lipid levels and lowdensity lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother 2008;9:669-76
5. Csaszar A. Vascular pleiosynergy - does it really work? Curr Vasc Pharmacol 2007;5:302-4
6. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004;109:II42-8
7. Paraskevas KI, Stathopoulos V, Mikhailidis DP. Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol 2008;6:237-9
8. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005;16:624-9
9. Dilaveris P, Giannopoulos G, Riga M, et al. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007;5:227-37
10. Paraskevas KI, Hamilton G, Mikhailidis DP. Statins: an essential component in the management of carotid artery disease. J Vasc Surg 2007;46:373-86
11. Paraskevas KI, Liapis CD, Hamilton G, et al. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? Eur J Vasc Endovasc Surg 2006;32:286-93
12. Sarafidis PA, Kanaki AI, Lasaridis AN. Effect of statins on blood pressure: a review of the experimental and clinical evidence. Curr Vasc Pharmacol 2007;5:155-61
13. Saratzis A, Saratzis N, Melas N, et al. Pharmacotherapy before and after endovascular repair of abdominal aortic aneurysms. Curr Vasc Pharmacol 2008;6:240-9
14. Kamishirado H, Inoue T, Sakuma M, et al. Effect of statins on restenosis after coronary stent implantation. Angiology 2007; 58:55-60
15. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases the risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2000;132:689-96
16. Ray JG, Mamdani M, Tsuyuki RT, et al. Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 2001;2001:1405-10
17. Ramcharan AS, van Stralen KJ, Snoep JD, et al. HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 2009;7:514-20
18. Doggen CJ, Lemaitre RN, Smith NL, et al. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004;2:700-1
19. Lacut K, Oger E, Le Gal G, et al. Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study. Fundam Clin Pharmacol 2004;18:477-82
20. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 2002;113:636-42
21. Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005;25:287-94
22. Kaba NK, Francis CW, Moss AJ, et al.; THROMBO Investigators. Effects of lipids and lipid-lowering therapy on hemostatic factors in patients with myocardial infarction. J Thromb Haemost 2004;2:718-25
23. Sen-Banerjee S, Mir S, Lin Z, et al. Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 2005;112:720-6
24. Nordenholz KE, Mitchell AM, Kline JA. Direct comparison of the diagnostic accuracy of fifty protein biological markers of pulmonary embolism for use in the emergency department. Acad Emerg Med 2008;15:795-9
25. Vormittag R, Funk M, Mannhalter C, et al. C-reactive protein 30 UTR +1444C>T polymorphism in patients with spontaneous venous thromboembolism. Atherosclerosis 2006;188:406-11
26. Kröger K, Weiland D, Ose C, et al. Risk factors for venous thromboembolic events in cancer patients. Ann Oncol 2006; 17:297-303
27. Tziomalos K, Athyros VG, Karagiannis A, et al. JUPITER: major implications for vascular risk assessment. Curr Med Res Opin 2009;25:133-7